Google
MGTX Stock Price & Analysis — Meiragtx Holdings PLC (Healthcare >> Biotechnology)
MGTX FAQ
What is MGTX's P/E ratio?
Meiragtx Holdings PLC (MGTX) currently trades at a P/E ratio of 72.92.
What is MGTX's ROE?
Meiragtx Holdings PLC reports a Return on Equity (ROE) of 207.35%.
What is MGTX's dividend yield?
Meiragtx Holdings PLC offers a dividend yield of 0.00%.
What is MGTX's Quality Score?
Our AI rates MGTX's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy MGTX?
Our AI Timing Score for MGTX is 67 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does MGTX belong to?
Meiragtx Holdings PLC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
MGTX AI Analysis Summary
Our AI summary for MGTX: Meiragtx Holdings PLC (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 72.92, ROE of 207.35%, a dividend yield of 0.00%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 67/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 12.29
Price
0.41
(3.45%)
Day Change
|
|
|---|
MGTX, the overall quality is not good ( Quality = 46) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/E ratio is relatively high
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 12.29 |
| PBV / Sector |
-18.93 / 44,022.72
|
| Earning Per Share | -1.35 |
| PE / Sector |
72.92 / 19.17
|
| PEG or PE/Growth / Sector |
-5.64 / 1.24
|
| Average 1M Daily Value |
7.73 M
|
| Average 1W Daily Value |
5.99 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
37% |
| Ability to Make Profit |
|
56% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-05 08:00:31 |
| Symbol | MGTX |
| Name | MEIRAGTX HOLDINGS PLC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 92.61 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,100.20 / 9,586.08 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 655 Third Avenue, New York, NY, United States, 10017
Phone: 646 860 7985
Website: https://www.meiragtx.com
Employees: 409
Sector: Healthcare >> Biotechnology
Description: MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase ½ clinical trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap